Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087198 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of T-TAS®01 HD Chip
A clinical trial, sponsored by Hikari Dx.
- Completed
- Registry status
- 43
- Enrollment target
NCT06087198: Completed study, sponsored by Hikari Dx.
NCT06087198 is a clinical trial that has completed, run by Hikari Dx. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06087198 has completed, sponsored by Hikari Dx.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
The study is being conducted to validate the clinical performance of the T-TAS 01 HD assay for measurement of thrombogenicity in patients with thrombocytopenia receiving a platelet transfusion.
Primary Outcome
Proportion of T-TAS 01 HD area under the curve (AUC) \< 700
Interventions
- DIAGNOSTIC_TEST T-TAS 01 HD Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-09-25 |
| Est. Completion | 2025-06-30 |
What the finished NCT06087198 record still lists
NCT06087198 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which T-TAS 01 HD Assay is the first listed.
NCT06087198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06087198 about?
NCT06087198 is a clinical study titled "Clinical Performance Evaluation of T-TAS®01 HD Chip". The study is being conducted to validate the clinical performance of the T-TAS 01 HD assay for measurement of thrombogenicity in patients with thrombocytopenia receiving a platelet transfusion.
What is the current status of trial NCT06087198?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2023-09-25. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT06087198?
The interventions under investigation include: T-TAS 01 HD Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06087198?
This trial is sponsored by Hikari Dx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI